| 1 |
CD2
💬
| 3件: Cell adhesion molecule (CAM) interaction Cell adhesion molecule (CAM) interaction, IgSF CAM signaling, Hematopoietic cell lineage | Siplizumab
Siplizumab
💬
|
Siplizumab
| 2件: 94 94, 95 💬
|
| 2 |
CD22
💬
| 3件: Cell adhesion molecule (CAM) interaction Cell adhesion molecule (CAM) interaction, Hematopoietic cell lineage, B cell receptor signaling pathway | Epratuzumab
Epratuzumab
💬
|
Epratuzumab
| 1件: 49 49 💬
|
| 3 |
CD274
💬
| 2件: Cell adhesion molecule (CAM) interaction Cell adhesion molecule (CAM) interaction, PD-L1 expression and PD-1 checkpoint pathway in cancer | Atezolizumab
Atezolizumab
💬
|
Atezolizumab
| 1件: 85 85 💬
|
| 4 |
CD274
💬
| 2件: Cell adhesion molecule (CAM) interaction Cell adhesion molecule (CAM) interaction, PD-L1 expression and PD-1 checkpoint pathway in cancer | Durvalumab
Durvalumab
💬
|
Durvalumab
| 1件: 85 85 💬
|
| 5 |
CD28
💬
| 13件: Cell adhesion molecule (CAM) interaction Cell adhesion molecule (CAM) interaction, IgSF CAM signaling, T cell receptor signaling pathway, Intestinal immune network for IgA production, Type I diabetes mellitus, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Autoimmune thyroid disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Viral myocarditis | Acazicolcept
Acazicolcept
💬
|
Acazicolcept
| 1件: 49 49 💬
|